For MPS I, Sangamo Therapeutics has developed ZFNs targeting intron 1 of the human albumin locus and a hIDUA donor construct with homology arms specific to the human albumin locus delivered using AAV6 vectors. The gene discussed is ALB; the disease is Scheie syndrome.